These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 27247220)
1. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220 [TBL] [Abstract][Full Text] [Related]
2. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789 [TBL] [Abstract][Full Text] [Related]
3. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323 [TBL] [Abstract][Full Text] [Related]
4. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial. Guberina M; Eberhardt W; Stuschke M; Gauler T; Heinzelmann F; Cheufou D; Kimmich M; Friedel G; Schmidberger H; Darwiche K; Jendrossek V; Schuler M; Stamatis G; Pöttgen C Ann Oncol; 2017 May; 28(5):1084-1089. PubMed ID: 28453703 [TBL] [Abstract][Full Text] [Related]
5. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy. Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123 [TBL] [Abstract][Full Text] [Related]
7. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). Eberhardt WE; Gauler TC; Lepechoux C; Stamatis G; Bildat S; Krbek T; Welter S; Grunenwald D; Fischer B; Rodrigo Hde L; Theegarten D; Le Chevalier T; Seeber S; Stuschke M; Poettgen C Lung Cancer; 2013 Oct; 82(1):83-9. PubMed ID: 23957964 [TBL] [Abstract][Full Text] [Related]
8. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967 [TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790 [TBL] [Abstract][Full Text] [Related]
11. Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome. Romine PE; Martins RG; Eaton KD; Wood DE; Behnia F; Goulart BHL; Mulligan MS; Wallace SG; Kell E; Bauman JE; Patel SA; Vesselle HJ BMC Cancer; 2019 Jan; 19(1):70. PubMed ID: 30642285 [TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642 [TBL] [Abstract][Full Text] [Related]
13. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420 [TBL] [Abstract][Full Text] [Related]
15. The predictive value of Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034 [TBL] [Abstract][Full Text] [Related]
16. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer. Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376 [TBL] [Abstract][Full Text] [Related]
17. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Pöttgen C; Levegrün S; Theegarten D; Marnitz S; Grehl S; Pink R; Eberhardt W; Stamatis G; Gauler T; Antoch G; Bockisch A; Stuschke M Clin Cancer Res; 2006 Jan; 12(1):97-106. PubMed ID: 16397030 [TBL] [Abstract][Full Text] [Related]
18. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery. Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175 [TBL] [Abstract][Full Text] [Related]
19. Tumour metabolic activity measured by fluorodeoxyglucose positron emission tomography for radiotherapy planning as a prognostic factor for locally advanced non-small cell lung cancer. Masarykova A; Scepanovic D; Povinec P; Bires P; Lederleitner D; Pobijakova M Bratisl Lek Listy; 2018; 119(3):133-138. PubMed ID: 29536740 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung. Roy S; Pathy S; Kumar R; Mohanti BK; Raina V; Jaiswal A; Taywade S; Garg K; Thulkar S; Mohan A; Mathur S; Behera D Nucl Med Commun; 2016 Feb; 37(2):129-38. PubMed ID: 26544097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]